Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
December 12, 2024
by PRNewswire
With personalized medicine, a shelved cancer drug could get another shot
A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer...
February 9, 2022
by WorldPharmaNews
Immune-Based Therapy Shows Promise Against Advanced Breast Cancers
An experimental therapy that harnesses the body's tumor-fighting immune cells...
February 9, 2022
by drugs.com
Puma Biotechnology’s NERLYNX Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment...
January 13, 2022
by FirstWordPharma
Metabolic vulnerabilities could be new targets for metastatic breast cancer
Metabolic differences could explain why some metastatic breast cancer cells rapidly generate tumors after migrating from primary tumors to the brain, while others linger for months or years before forming these secondary tumors...
January 13, 2022
by FirstWordPharma
Overall Breast Cancer Incidence Decreased From 1999 to 2018
The incidence of breast cancer decreased overall from 1999 to 2018, but incidence increased among women aged 20 to 39 years and for non-Hispanic...
January 13, 2022
by drugs.com
Tailored Strategies Can Up Depression Referrals in Breast Cancer
For patients with newly diagnosed breast cancer, tailored strategies for implementation of routine depression screening result in a greater proportion of referrals to behavioral care, according to a study published in the Jan. 4 issue of the Journal of th
January 4, 2022
by drugs
Breast Cancer Survival Up With Access to Integrative Therapies
Institutional involvement in integrative oncology may increase survival for breast cancer patients, according to a study published online Dec. 18 in the Journal of Oncology.
December 29, 2021
by drugs
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B.
December 28, 2021
by prnasia
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
December 15, 2021
by prnasia
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") provided details on the elacestrant data from the EMERALD trial following the positive results presented today...
December 13, 2021
by prnasia
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical treatment...
December 10, 2021
by prnasia